" class="no-js "lang="en-US"> H1 and Lokavant Partner on Data and Analytics to Power Next Generation Clinical Trials - Medtech Alert
Friday, February 03, 2023

H1 and Lokavant Partner on Data and Analytics to Power Next Generation Clinical Trials

H1, the connecting force for global HCP, clinical, scientific, and research information, and Lokavant, the leading clinical trial intelligence company, today announced an extensive data-and-analytics collaboration to bring enhanced automated intelligence to drug development. As part of the bi-directional partnership, Lokavant will provide performance data on global trial sites and principal investigators from thousands of studies to supplement H1’s existing Trial Landscape clinical trial repository.

“The trial performance data supplied by the Lokavant-H1 partnership empowers enhanced analytics capabilities and data insights which will help clinical teams access the right investigators to run their trials,” said Ariel Katz, H1 CEO and co-founder. “We see a natural symbiosis with Lokavant to put the power of H1 Trial Landscape in the hands of clinical researchers who are bringing new hope to patient populations around the world.”

Lokavant’s trial performance data is linked to the detailed HCP quality and outcome data from H1’s broad repository of investigator experience, and drives the development of advanced analytics for study planning. Furthermore, Lokavant’s data will be complemented with the H1 clinical data elements, powering Lokavant’s predictive models to drive novel insights on site and investigator performance. This partnership generates the most comprehensive data repositories in clinical research on global investigator, site and operational trial data.

“Integrating H1’s unparalleled wealth of clinical trial data sources into our Intelligence platform will provide clinical operations teams with optimal insights needed to plan and execute their clinical studies more effectively, ultimately reducing the time it takes to get life-changing medicines to patients,” said Rohit Nambisan, Lokavant’s CEO and Co-founder. “This truly is a case where, for patients, the whole is far greater than the sum of the parts.”

This partnership will also fuel H1’s Trial Landscape platform with novel metrics to help trial teams analyze and profile the best sites for their trial based on trial performance information, experience and patient access. With this approach, trial teams will be able to rapidly identify which investigators have access to the right patient populations, support their commitments to diversity in HCPs and subjects, and profile investigators by their ability to run timely, high quality trials in the relevant indication.

People In This Post

Companies In This Post

  1. Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer Read more
  2. Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials Read more
  3. Trelleborg to Expand its BioPharmaceutical Manufacturing Footprint in Europe Read more
  4. Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch Read more
  5. Accenture Expands Strategy Capabilities in Life Sciences with the Acquisition of Bionest Read more